うつ病治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Depression - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0926
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:668
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Depression – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Depression – Pipeline Review, H1 2020, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Depression – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 16, 36, 42, 4, 86, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 13 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Depression – Overview
Depression – Therapeutics Development
Depression – Therapeutics Assessment
Depression – Companies Involved in Therapeutics Development
Depression – Drug Profiles
Depression – Dormant Projects
Depression – Discontinued Products
Depression – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Depression, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Depression - Pipeline by Acadia Pharmaceuticals Inc, H1 2020
Depression - Pipeline by Adamed Sp zoo, H1 2020
Depression - Pipeline by Addex Therapeutics Ltd, H1 2020
Depression - Pipeline by Aequus Pharmaceuticals Inc, H1 2020
Depression - Pipeline by Aision Biotechnologies Inc, H1 2020
Depression - Pipeline by Alkermes Plc, H1 2020
Depression - Pipeline by Allergan Plc, H1 2020
Depression - Pipeline by Amorsa Therapeutics Inc, H1 2020
Depression - Pipeline by Anavex Life Sciences Corp, H1 2020
Depression - Pipeline by Angelini Group, H1 2020
Depression - Dormant Projects, H1 2020
Depression - Discontinued Products, H1 2020

【掲載企業】

Acadia Pharmaceuticals Inc
Adamed Sp zoo
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc
Aision Biotechnologies Inc
Alkermes Plc
Allergan Plc
Amorsa Therapeutics Inc
Anavex Life Sciences Corp
Angelini Group
Antheia Inc
Asulon Therapeutics Inc
Atai Life Sciences AG
Avanir Pharmaceuticals Inc
Avicanna Inc
Axsome Therapeutics Inc
Azevan Pharmaceuticals Inc
Baergic Bio Inc
Beloteca Inc
Bionomics Ltd
BioStem Technologies Inc
BioXcel Therapeutics Inc
Blackthorn Therapeutics Inc
Blue Oak Pharmaceuticals Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calico LLC
Cellix Bio Pvt Ltd
Celon Pharma SA
CGeneTech (Suzhou China) Co Ltd
Chase Therapeutics Corp
Clera Inc
Clexio Biosciences Ltd
Compass Pathways Ltd
CSPC Pharmaceutical Group Ltd
CuroNZ Ltd
Delpor Inc
Denovo Biopharma LLC
Douglas Pharmaceuticals Ltd
Dracen Pharmaceuticals Inc
Eisai Co Ltd
Eleusis Ltd
Eli Lilly and Co
ES Therapeutics LLC
Evecxia Inc
Evotec SE
Fabre-Kramer Pharmaceuticals Inc
Gabather AB
GlaxoSmithKline Plc
GliaCure Inc
GNT Pharma Co Ltd
Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
H. Lundbeck AS
HEC Pharm Co Ltd
HolsboerMaschmeyer NeuroChemie GmbH
Hua Medicine Shanghai Ltd
Iltoo Pharma
Impel NeuroPharma Inc
Initiator Pharma AS
Intas Pharmaceuticals Ltd
IntelGenx Corp
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Gibel Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Jina Pharmaceuticals Inc
Johnson & Johnson
Kamat Pharmatech LLC
Kissei Pharmaceutical Co Ltd
Klaria Pharma Holding AB
Krenitsky Pharmaceuticals Inc
Kures Inc
Lactocore Inc
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Ligand Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Luye Pharma Group Ltd
Lyndra Inc
Mapreg SAS
Marinus Pharmaceuticals Inc
MD Healthcare Inc
Medlab Clinical Ltd
MElkin Pharmaceuticals
Mental-Heal Ltd
Meta-IQ ApS
Methylation Sciences Inc
miCure Therapeutics Ltd
Navitor Pharmaceuticals Inc
Neurocentrx Pharma Ltd
Neurocrine Biosciences Inc
Neurocyte Therapeutics Inc
Neurolixis Inc
NeuroNascent Inc
NeuroRx Inc
Neurotrope Bioscience Inc
Nippon Chemiphar Co Ltd
Novartis AG
Nubiyota LLC
Omeros Corp
Orbis Biosciences Inc
Orexigen Therapeutics Inc
Otsuka Holdings Co Ltd
Otsuka Pharmaceutical Co Ltd
Overseas Pharmaceuticals Ltd
OWP Pharmaceuticals Inc
Pfizer Inc
PharmaMax Corp
Pharmnovo AB
PharmoRx Therapeutics Inc
Phenoquest AG
Phytecs
PNB Vesper Life Science Pvt Ltd
Praxis Precision Medicines Australia Pty Ltd
Primetime Life Sciences LLC
Protagenic Therapeutics Inc
Prous Institute for Biomedical Research SA
Psy Therapeutics Inc
Relmada Therapeutics Inc
Repurposed Therapeutics Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Sage Therapeutics Inc
Saniona AB
Seelos Therapeutics, Inc.
Seneca Biopharma Inc
Shanghai SIMR Biotech Co Ltd
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Shenox Pharmaceuticals LLC
Siragen Pharmaceuticals Inc
SK Biopharmaceuticals Co Ltd
Small Pharma Ltd
Sosei Heptares
Sound Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
SyneuRx International Corp
Syntropharma Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Techfields Pharma Co Ltd
Terran Biosciences Inc
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Vanda Pharmaceuticals Inc
VistaGen Therapeutics Inc
WhanIn Pharmaceutical Co Ltd
XW Laboratories Inc
Yantai YenePharma Co Ltd
Yungjin Pharm Co Ltd
Zhejiang Jinhua Conba Bio-pharm Co Ltd
Zysis Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[うつ病治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆